Viral Hepatitis in Asia and the Pacific

Dr. Sun is the Associate Professor of Pharmaceutical Policy. Her research areas focus on pharmaceutical policy analysis and specialized in pharmaco-economics and pharmaco-epidemiology. She received her Ph.D. from the Graduate School of Medical Sciences at the University of Groningen of the Netherlands, MSc. of International Health Policy from London School of Economics of UK, and Bachelor of Pharmaceutical Chemistry from Peking Medical University of China. Dr Chan is the Medical Officer of WHO. She has been serving WHO since 2005 in prevention and control of communicable diseases. Dr Chan graduated from the London School of Hygiene and Tropical Medicine in Epidemiology and Tropical Medicine and Hygiene, she was trained in Medicine and Surgery at the University of Hong Kong.​ Ms Chee is the Director of Third World Network, a non-profit international policy research and advocacy organization involved in sustainable development issues. She is an international lawyer whose areas of expertise include the environmental, social and economic impacts of globalization, especially in countries of the South. She is trained in international law, with degrees from the University of Malaya in Malaysia and Cambridge University of UK.

1. Global background and overview of the epidemiology and responses to viral hepatitis the Asia-Pacific region
2. Universal medicine access through lump-sum remuneration-Australia's approach to hepatitis C
3. A simplified service model integrated in an existing public health system-De-centralised hepatitis C testing and treatment in Cambodia
4. Central pooled procurement and price negotiation -China’s strategy to make antivirals for hepatitis B & C treatment affordable
5. Micro-elimination of viral hepatitis in India Punjab state
6. Government-led initiatives-A Journey of improving hepatitis C treatment accessibility in Malaysia
7. The first lower-middle-income country in the Asia-Pacific region to commit to hepatitis elimination-The Healthy Liver Programme in Mongolia
8. Universal hepatitis B immunization
9. Barriers to achieve the 2030 targets for elimination of viral hepatitis and coherent public health policies to address the viral hepatitis challenges in the region
10. The ‘how’ of shifting a global paradigm: from dual to triple elimination of HIV, syphilis and viral hepatitis B